Radiographic
Progression

Discover Strength of Balance

FINCH 1 – MTX-IR

JYSELECA inhibits radiographic progression in MTX-IR patients (p<0.001 vs. MTX at Week 24)2,7

Change from baseline in mTSS


88% of patients on JYSELECA showed zero radiographic progression§ at week 52 (vs. 82% of adalimumab patients)7

Adapted from Combe B, et al. 20212
*p<0.001 vs. MTX alone + placebo,
†p<0.001 vs. adalimumab.
‡52-week data were not controlled for multiplicity.
§Defined as change from baseline in mTSS ≤0.

FINCH 3 – MONOTHERAPY

Monotherapy with JYSELECA successfully inhibited radiographic progression4

Change from baseline in mTSS


84% of JYSELECA patients had no radiographic progression§ at week 52
(vs. 78% of patients receiving MTX)9

Adapted from Westhovens R, et al. 20214
Nominal p values: *p<0.001, †p<0.01 vs. MTX + placebo.
‡52-week data were not controlled for multiplicity.
§Defined as change from baseline in mTSS ≤0.


Discover Strength of Balance

ACR Data
 

 


DAS28-CRP Remission




Head-to-Head vs. Adalimumab



JYSELECA is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).1 JYSELECA may be used as monotherapy or in combination with methotrexate (MTX).1

References: 1. JYSELECA SPC. Available at: www.medicines.org.uk / www.medicines.ie. Last accessed: October 2022. 2. Combe B, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219214. 3. Genovese MC, et al. JAMA 2019;322 (4):315–325. 4. Westhovens R, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219213. 5. Combe B, et al. Arthritis Rheumatol 2021;73(suppl 10). https://acrabstracts.org/abstract/integrated-safety-analysis-update-for-filgotinib-in-patients-with-moderately-to-severely-active-rheumatoid-arthritis-receiving-treatment-over-a-median-of-2-2-years/. Last accessed: October 2022. 6. Buch MH, et al. Arthritis Rheumatol 2021;73 (suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-ongoing-filgotinib-ra-long-term-extension-trial-of-biologic-dmard-inadequate-responders-initially-on-filgotinib-or-placebo-in-a-phase-3-trial/. Last accessed: October 2022. 7. Data on file - Gilead Sciences Ltd - INF-UK-20-04. 8. Data on file - Gilead Sciences Ltd - INF-UK-20-06. 9. Data on file - Gilead Sciences Ltd - INF-UK-20-11.